A 19-year-old won $100,000 for inventing a cheaper, faster way to make antiviral drugs out of corn husks
Adam Kovalčík, age 19, innovated a cheaper, faster way to produce an antiviral drug.
Galidesivir targets RNA viruses like COVID-19, Ebola, and Zika but hasn't completed clinical trials.
Kovalčík won a $100,000 science fair award for using corn waste to synthesize the drug.
When Adam Kovalčík flew to Ohio for an international science competition, he did not expect to come home with $100,000.
The 19-year-old from Dulovce, Slovakia won that sum on Friday, though, because he developed a faster and cheaper way to make an experimental antiviral drug called galidesivir, which targets RNA viruses like COVID-19, Ebola, and Zika virus.
"This could be a huge step to help prevent some of these RNA viruses," Chris RoDee, a chemist and retired patent examiner, told Business Insider.
Early studies have shown galidesivir can attack RNA viruses, but it has not undergone full clinical trials. Kovalčík thinks he can encourage further research by slashing the cost of producing the drug — from $75 per gram to about $12.50 per gram.
That's because he used corn waste to synthesize twice as much of the drug in just 10 steps, rather than the 15 steps currently required for manufacturing.
Kovalčík even went one step further: He used his method to make a new drug that could also fight RNA viruses.
Kovalčík presented his findings at the Regeneron International Science and Engineering Fair (ISEF) in Columbus, Ohio, this week. The judging committee, which RoDee chaired, chose Kovalčík for the competition's top prize: the $100,000 George D. Yancopoulos Innovator Award.
"I cannot describe this feeling," Kovalčík told BI after receiving the award in a lively ceremony on Friday. "I did not expect such a huge international competition to be won by someone from a small village in a small European country, so it was just pure shock."
Student research at ISEF does not go through the rigorous peer-review process that studies pass before they're published in scientific journals.
However, RoDee said that Kovalčík's chemistry was "really elegant" and his presentation to the judges was "bulletproof."
Kovalčík's big cost-saving innovation started with corn husks.
Well, it started with furfuryl alcohol, which comes from corn husks and is relatively cheap compared to other starting points for making drugs.
One by one, Kovalčík added chemicals to a flask of furfuryl alcohol in the lab, like building blocks adding to the molecule, until he got a crucial sugar called aza-saccharide. It only took seven steps to get there.
From there, it was only three more steps to get galidesivir.
"He was able to shortcut this entire process," RoDee said. "He basically halved the number of steps because he just went in through a different door."
Kovalčík's process takes five days. The conventional manufacturing method, he said, takes nine days.
Eventually, he produced another drug, too. Based on early computer calculations, Kovalčík thinks his new molecule could be five times as effective as galidesivir against COVID-19 — binding more strongly to enzymes to kill the virus.
Kovalčík said he's filed a preliminary patent on his drug-synthesis process.
He also plans to work more with a research group at the Slovak University of Technology in Bratislava, which has supported his project so far.
To be used commercially, Kovalčík's drug-manufacturing process would have to scale up. At the moment, he said, he's struggling to find a way to make more than 200 liters of galidesivir.
He also plans to work with the university researchers on improving other drug-synthesis processes.
"They actually have much more designs and much more new drugs to prepare and test," he said.
Kovalčík's ambitions don't end with advancing drug manufacturing, though. He said he also wants to use his chemistry skills and prize money to start a company that manufactures eco-friendly perfumes from corn.
"From the first time I stepped foot into a lab, I knew that I wanted to do something related to chemistry," Kovalčík said.
Now that he's won recognition for it, he added, "I feel incredible."
Read the original article on Business Insider

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Medical Flexible Packaging Market Size worth $27.72 billion, Globally, by 2030- Exclusive Study by The Research Insights
CHICAGO, June 2, 2025 /PRNewswire/ -- The global medical flexible packaging market size is projected to be valued at USD 20.22 billion in 2024 and reach USD 27.72 billion by 2030, growing at a CAGR of 5.4% according to a new report by The Research Insights. The medical flexible packaging market share is expanding at a fast pace because healthcare providers are moving towards disposable medical products. Medical institutions and professionals are now placing hygiene and safety at the forefront of their priorities because infection control has gained unprecedented importance after global health emergencies such as COVID-19. Clinical environments now standardize single-use products like syringes and surgical instruments to protect patients by reducing cross-contamination risks. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the medical flexible packaging market share growth of 5.4% comprises a range of material, product, end-use and geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Medical Flexible Packaging Industry, Download FREE Sample Pages: Market Overview and Growth Trajectory: Medical Flexible Packaging Industry Growth: According to an exhaustive report by The Research Insights, the Medical Flexible Packaging Market share is undergoing significant growth, driven by innovations in bio-based polymers together with recyclable materials transform the medical flexible packaging industry operations. Medical flexible packaging market leaders are developing new solutions because of increasing environmental concerns by implementing biodegradable and recyclable flexible films. Healthcare packaging is moving toward sustainable materials which reflects both environmental consciousness and a strategic alignment with worldwide sustainability objectives. Rising Demand for Sterile Packaging: Sterility in healthcare serves as a fundamental lifeline beyond being just a standard requirement. Patient safety depends on medical products such as surgical instruments, pre-filled syringes and wound dressings remaining uncontaminated until they reach their point of use. The rising focus on infection prevention creates greater need for sterile packaging which propels growth in the medical flexible packaging market. Medical professionals prefer sterilizable pouches, peelable sachets, and breathable wraps in flexible packaging because these formats deliver ideal protection alongside ease of use and regulatory compliance. The need for sterile medical packaging which offers convenience and cost-effectiveness will become even more significant as healthcare demands worldwide grow particularly in home care and outpatient settings. The medical flexible packaging market leads the way in this transformation by providing necessary innovations and flexible solutions to ensure safe and dependable medical care. For Detailed Market Insights, Visit: Innovation in Smart Packaging: Modern packaging serves multiple purposes beyond protection by acting as a smart device that improves safety measures and creates opportunities for product traceability and customer interaction. The medical flexible packaging market demonstrates this transformation through the revolutionary integration of smart technologies like QR codes, NFC (Near Field Communication), and time-temperature indicators which changes how medical products are tracked and managed. Smart packaging protects patients by verifying medical product authenticity and monitoring proper storage and use practices. The system aids manufacturers in regulatory compliance by allowing them to track products across their supply chain while monitoring environmental conditions and generating comprehensive records for audits. This transparency level enables healthcare providers and pharmacies to minimize errors and protect against counterfeit product use. The medical flexible packaging market is developing in parallel with the growing connectivity and personalization of healthcare services. Incorporating smart technologies enables this industry to deliver more than products by offering confidence and safety through innovative intelligent pouches. Pouches and Bags Dominate for Their Versatility and Sterility Assurance: The medical flexible packaging market prefers pouches and bags because they offer unmatched versatility along with sterility maintenance and adaptability to numerous medical uses. Medical professionals choose these packaging formats for surgical instruments, diagnostic kits, and pharmaceutical products because they provide strong protection from contaminants and support multiple sterilization techniques including EtO, steam, and gamma radiation. Medical facilities benefit from their lightweight form, customizability, and simple storage options because these features support critical needs for space efficiency and quick accessibility. As single-use medical products become more sought after they drive wider usage of pouches and bags which establish them as the leading choice in the medical flexible packaging market that continues to grow. Stay Updated on The Latest Medical Flexible Packaging Market Trends: Geographical Insights: The medical flexible packaging market share in North America maintains its strong position because of its advanced healthcare infrastructure combined with strict regulatory standards alongside high adoption of innovative packaging technologies. Demand for sterile single-use packaging in the region remains robust because of its role in maintaining infection control standards and ensuring patient safety. The medical flexible packaging market size in the Asia Pacific region is growing quickly because of enhanced healthcare access and pharmaceutical production alongside population growth. Hospital infrastructure and medical manufacturing investments have increased in China, India, and Japan which drives the need for affordable and efficient packaging solutions. The European medical flexible packaging market focuses heavily on sustainable practices alongside compliance with regulations and maintaining high quality standards. The region leads the adoption of recyclable and bio-based flexible packaging materials while supporting EU green initiatives and environmental legislation. Medical Flexible Packaging Market Segmentation and Geographical Insights: Based on material, the medical flexible packaging market share is divided into plastics, paper, aluminum and bioplastics. The plastics segment held the largest share of the medical flexible packaging market in 2024. Based on product, the medical flexible packaging market size is divided into seals, high barrier films, wraps, pouches & bags, lids & labels and others. The pouches & bags segment held the largest share of the medical flexible packaging market in 2024. Based on end-use, the medical flexible packaging market share is divided into pharmaceutical manufacturing, medical device manufacturing, implant manufacturing, contract packaging and others. The pharmaceutical manufacturing segment accounted for a larger share of the medical flexible packaging market in 2024. The medical flexible packaging market report is segmented into five major regions: North America, Europe, Asia Pacific, Central & South America and Middle East & Africa. Purchase Premium Copy of Global Medical Flexible Packaging Market Size and Growth Report (2024-2030) at: Key Players and Competitive Landscape: The Medical Flexible Packaging Market is characterized by the presence of several major players, including: Amcor plc AptarGroup, Inc. BD (Becton, Dickinson and Company) Klöckner Pentaplast Winpak Ltd. Sealed Air Corporation Coveris Oliver Healthcare Packaging Nelipak Healthcare Packaging Constantia Flexibles Glenroy Inc. ProAmpac UFlex Limited Eagle Flexible Packaging These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. Medical Flexible Packaging Market Recent Developments and Innovations: In May 2025, Nelipak announced plans to establish a new packaging production site in Grecia, Alajuela, Costa Rica. The 60,000-square-foot facility will enhance Nelipak's capacity to support the growing medical device manufacturing community in the region, with operations expected to commence by mid-2026. In November 2024, Amcor announced its acquisition of Berry Global in an $8.4 billion all-stock deal. The combination brings together two highly complementary businesses to create a global leader in consumer packaging solutions, with a broader flexible film and converted film offering for customers, a scaled containers and closures business and a unique global healthcare portfolio. In February 2024, AptarGroup, Inc. collaborated with ProAmpac to introduce the ProActive Intelligence Moisture Protect (MP-1000). This next-generation platform combines Aptar's Activ-Polymer technology with ProAmpac's flexible blown film technology to create a moisture-absorbing flexible medical device packaging solution. For Region-Specific Market Data, Check Out Brief Sample Pages: Key Questions Addressed: 1. What is the key opportunity in the medical flexible packaging market? Ø Development of eco-friendly medical flexible packaging materials (e.g., bio-based films) presents a growth opportunity aligned with sustainability goals. 2. What is the expected market size for medical flexible packaging market by 2030? Ø The expected market size for medical flexible packaging is USD 27.72 Billion in 2030. 3. Which are the major end uses where medical flexible packaging is used? Ø Major end uses includes pharmaceutical manufacturing, medical device manufacturing, implant manufacturing, contract packaging and others. 4. Which product segment for medical flexible packaging market has the potential to register the highest market share? Ø Pouches & bags segment for medical flexible packaging market is expected to register highest market share of 36% in 2024. 5. Which region is estimated to witness a high demand for medical flexible packaging over the forecast period? Ø Asia Pacific is estimated to witness a high demand for medical flexible packaging growing at a CAGR of 6.7% over the forecast period 6. Who are the key players in medical flexible packaging market? Ø The key players in the market are Amcor plc, AptarGroup, Inc., BD (Becton, Dickinson and Company), Klöckner Pentaplast, Winpak Ltd., Sealed Air Corporation, Coveris, Oliver Healthcare Packaging, Nelipak Healthcare Packaging, Constantia Flexibles, Glenroy Inc., ProAmpac, UFlex Limited and Eagle Flexible Packaging. Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: Conclusion: Technological advancements alongside sustainability initiatives and strategic company mergers are driving major changes in the medical flexible packaging market while regional growth continues to expand its scope. The medical packaging landscape shows North America as the leader in sterile packaging advances and technological implementation whereas Europe focuses on recyclable packaging solutions that meet regulatory requirements. The Asia-Pacific region experiences rapid growth because of expanding pharmaceutical operations and rising healthcare expenditures. The medical flexible packaging market shows strong growth potential from its essential function in product safety improvement as well as its support for sustainable healthcare practices while providing adaptable manufacturing solutions that fulfill the rigorous requirements of the global medical sector. The report from The Research Insights, therefore, provides several stakeholders—including raw material suppliers, film & laminate manufacturers, packaging converters, pharmaceutical companies, contract packaging organizations (CPOs), distributors and end users —with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 27.72 billion by 2030, the Medical Flexible Packaging Market represents a significant opportunity for raw material suppliers, film & laminate manufacturers, packaging converters, pharmaceutical companies, contract packaging organizations (CPOs), distributors, end-users, investors, industry stakeholders, and others. By staying abreast of market trends, embracing innovation, and focusing on quality and performance, companies can position themselves for success in this dynamic and evolving market landscape. Check out more related studies published by The Research Insights: Flexible Packaging Market - The global flexible packaging market size is expected to reach USD 373.34 billion by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 4.8% from 2024 to 2030. The growing demand can be attributed to the multifaceted benefits offered by flexible packaging products. These include an array of container options, reduced raw material requirements, convenient disposal methods, and lightweight nature, which collectively contribute to their popularity among consumers and industries alike. Pharmaceutical Packaging Market - The global pharmaceutical packaging market size is expected to reach USD 251.6 billion by 2034, according to a new report by The Research Insights. It is projected to register a CAGR of 6.1% during the forecast period, driven largely by the rapid expansion of the pharmaceutical industry. The sector's steady rise can be attributed to advancements in science and technology, which have been instrumental in enhancing product efficacy and safety. Pharmaceutical Contract Packaging Market - The global pharmaceutical contract packaging market size is anticipated to reach USD 26.2 billion by 2030 and is projected to grow at a CAGR of 7.1% from 2025 to 2030, according to a new report by The Research Insights. This upward trend can be attributed to the increasing tendency among pharmaceutical companies to outsource their packaging operations to specialized firms. Medical Device Packaging Market - The global medical device packaging market size is anticipated to reach USD 55.1 billion by 2030, according to a new report by The Research Insights, expanding at a CAGR of 6.3% from 2025 to 2030. The global medical device packaging market is poised to expand significantly, driven by the increasing requirement for effective and efficient packaging solutions that cater to the diverse needs of medical devices. Browse More related reports on Specialty & Chemicals Market – About The Research Insights: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Website: Latest News: | | Logo: View original content to download multimedia: SOURCE The Research Insights Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Moderna Stock Climbs as FDA Approves New COVID-19 Vaccine
Moderna said the FDA approved its new COVID-19 vaccine "for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor." Shares of the pharmaceutical giant rose Monday morning but are still down by nearly 35% this year. Moderna's original COVID-19 vaccine generated $3.1 billion in sales last of Moderna (MRNA) climbed Monday after the Food and Drug Administration (FDA) approved the drugmaker's new COVID-19 vaccine. Moderna said its new vaccine, mNEXSPIKE, showed a higher relative efficacy in a clinical trial than its first FDA-approved COVID-19 vaccine and was approved "for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC)." The Cambridge, Mass.-based company said it "expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA, the Company's approved respiratory syncytial virus (RSV) vaccine." Moderna's original COVID-19 vaccine, Spikevax, generated $3.1 billion in sales last year. Moderna shares rose 2% soon after markets opened but have lost nearly 35% of their value in 2025. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Miami Herald
an hour ago
- Miami Herald
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).[1] "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial ( Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax®), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older. In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia. Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA®, the Company's approved respiratory syncytial virus (RSV) vaccine. mRNA-1283 is under review with regulators in multiple markets around the world. About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mNEXSPIKE®, mRESVIA® and Spikevax®are registered trademarks of Moderna. INDICATION mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are: • 65 years of age and older, or • 12 years through 64 years of age at high risk for severe COVID-19. Vaccination with mNEXSPIKE may not protect all people who receive the vaccine. IMPORTANT SAFETY INFORMATION You should not get mNEXSPIKE if you hada severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines. What are the risks of mNEXSPIKE?There is a very small chance that mNEXSPIKE could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include: Trouble breathingSwelling of your face and throatA fast heartbeatA rash all over your bodyDizziness and weakness Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine: Chest painShortness of breathFeelings of having a fast-beating, fluttering, or pounding heart Side effects that have been reported in clinical trials with mNEXSPIKE include: Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever Tell your vaccination provider about all of your medical conditions, including if you: have any allergieshad a severe allergic reaction after receiving a previous dose of any COVID-19 vaccinehave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)have a feverhave a bleeding disorder or are on a blood thinnerare immunocompromised or are on a medicine that affects your immune systemare pregnant or plan to become pregnantare breastfeedinghave received any other COVID-19 vaccinehave ever fainted in association with an injection These may not be all the possible side effects of mNEXSPIKE. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mNEXSPIKE Full Prescribing Information. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mNEXSPIKE; and the availability of Moderna's respiratory vaccines for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna ContactsMedia:Chris RidleyHead of Global Media Relations+1 Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1